Gregg Semenza, MD, PhD: The Role of HIF-1 and HIF-2 in Cancer

Gregg L. Semenza, MD, PhD, was recently awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work in isolating hypoxia inducible factor (HIF) 1, which controls genes that are involved in cells' adaptation to low oxygen levels, with implications for cancer, ischemia, and chronic lung disease. In this interview with i3 Health, Dr. Semenza discusses the involvement of HIF-1 and HIF-2 in cancer and shares insights on the progress that is being made in developing HIF-1 and HIF-2 i...
Continue reading

Strategies to Optimize Multiple Myeloma Treatment With Carol Ann Huff, MD

Because multiple myeloma frequently remains asymptomatic until the disease is in the advanced stages, it can be difficult to diagnose and has limited treatment options, resulting in a five-year survival rate of only 50.7%. In this Q&A session from i3 Health's live meeting series, Evolving Treatment Paradigms in Multiple Myeloma and Implications for Shared Decision Making, Carol Ann Huff, MD, Medical Director for the Johns Hopkins Kimmel Cancer Center, discusses strategies to enhance the trea...
Continue reading

Treating Multiple Myeloma: Challenges, Solutions, and Research Advances With Carol Ann Huff, MD

​With a five-year survival rate of only 50.7%, multiple myeloma remains difficult to treat. In this interview with i3 Health, Carol Ann Huff, MD, Medical Director for the Johns Hopkins Kimmel Cancer Center, explores the challenges and research advances of myeloma treatment. She also gives advice on helping patients to find assistance with the prohibitive costs of treatment and on handling the difficulties involved in treating patients at smaller community cancer centers, including patients who l...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.